Venus MedTech Reports 18.9% Drop in Revenue and 35.5% Decrease in Net Loss for H1 2025; EPS Improves by 34.0%

Reuters

Aug 28

Venus MedTech Reports 18.9% Drop in Revenue and 35.5% Decrease in Net Loss for H1 2025; EPS Improves by 34.0%

Venus MedTech (Hangzhou) Inc. has announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported a revenue of RMB 187.1 million for the period, reflecting an 18.9% decrease compared to RMB 230.7 million for the same period in 2024. The gross profit also saw a decline of 24.1%, dropping from RMB 181.8 million in 2024 to RMB 138.0 million in 2025. The company reported a loss before tax of RMB 138.6 million, which is a 35.1% improvement over the loss of RMB 213.6 million recorded in the same period of the previous year. The loss for the period amounted to RMB 134.8 million, a 35.5% reduction from the RMB 208.8 million loss in the first half of 2024. Venus MedTech continues its focus on the research, development, manufacturing, and sale of bioprosthetic heart valves. The company was listed on the Main Board of The Stock Exchange of Hong Kong Limited on December 10, 2019.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2562034109"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562034109\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562034109?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 20:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562034109","market":"us","top_or_hot":-1,"title":"Venus MedTech Reports 18.9% Drop in Revenue and 35.5% Decrease in Net Loss for H1 2025; EPS Improves by 34.0%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Venus MedTech Reports 18.9% Drop in Revenue and 35.5% Decrease in Net Loss for H1 2025; EPS Improves by 34.0%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Venus MedTech (Hangzhou) Inc. has announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported a revenue of RMB 187.1 million for the period, reflecting an 18.9% decrease compared to RMB 230.7 million for the same period in 2024. The gross profit also saw a decline of 24.1%, dropping from RMB 181.8 million in 2024 to RMB 138.0 million in 2025. The company reported a loss before tax of RMB 138.6 million, which is a 35.1% improvement over the loss of RMB 213.6 million recorded in the same period of the previous year. The loss for the period amounted to RMB 134.8 million, a 35.5% reduction from the RMB 208.8 million loss in the first half of 2024. Venus MedTech continues its focus on the research, development, manufacturing, and sale of bioprosthetic heart valves. The company was listed on the Main Board of The Stock Exchange of Hong Kong Limited on December 10, 2019.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Venus MedTech Reports 18.9% Drop in Revenue and 35.5% Decrease in Net Loss for H1 2025; EPS Improves by 34.0%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVenus MedTech Reports 18.9% Drop in Revenue and 35.5% Decrease in Net Loss for H1 2025; EPS Improves by 34.0%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-28 20:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Venus MedTech Reports 18.9% Drop in Revenue and 35.5% Decrease in Net Loss for H1 2025; EPS Improves by 34.0%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Venus MedTech (Hangzhou) Inc. has announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported a revenue of RMB 187.1 million for the period, reflecting an 18.9% decrease compared to RMB 230.7 million for the same period in 2024. The gross profit also saw a decline of 24.1%, dropping from RMB 181.8 million in 2024 to RMB 138.0 million in 2025. The company reported a loss before tax of RMB 138.6 million, which is a 35.1% improvement over the loss of RMB 213.6 million recorded in the same period of the previous year. The loss for the period amounted to RMB 134.8 million, a 35.5% reduction from the RMB 208.8 million loss in the first half of 2024. Venus MedTech continues its focus on the research, development, manufacturing, and sale of bioprosthetic heart valves. The company was listed on the Main Board of The Stock Exchange of Hong Kong Limited on December 10, 2019.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02500","symbol_name":"启明医疗-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL1vpWv7:1","article_id":"2562034109","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562034109","pubTimestamp":1756383448,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Venus MedTech  Inc. has announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported a revenue of RMB 187.1 million for the period, reflecting an 18.9% decrease compared to RMB 230.7 million for the same period in 2024. The gross profit also saw a decline of 24.1%, dropping from RMB 181.8 million in 2024 to RMB 138.0 million in 2025. The company reported a loss before tax of RMB 138.6 million, which is a 35.1% improvement over the loss of RMB 213.6 million recorded in the same period of the previous year. The loss for the period amounted to RMB 134.8 million, a 35.5% reduction from the RMB 208.8 million loss in the first half of 2024. Venus MedTech continues its focus on the research, development, manufacturing, and sale of bioprosthetic heart valves. The company was listed on the Main Board of The Stock Exchange of Hong Kong Limited on December 10, 2019.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"02500":"启明医疗-B"},"translate_title":"Venus MedTech报告称，2025年上半年收入下降18.9%，净亏损下降35.5%；每股收益提高34.0%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02500":0.9},"content_text":"Venus MedTech Reports 18.9% Drop in Revenue and 35.5% Decrease in Net Loss for H1 2025; EPS Improves by 34.0%\n    \n\n        Venus MedTech (Hangzhou) Inc. has announced its unaudited consolidated interim results for the six months ended June 30, 2025. The company reported a revenue of RMB 187.1 million for the period, reflecting an 18.9% decrease compared to RMB 230.7 million for the same period in 2024. The gross profit also saw a decline of 24.1%, dropping from RMB 181.8 million in 2024 to RMB 138.0 million in 2025. The company reported a loss before tax of RMB 138.6 million, which is a 35.1% improvement over the loss of RMB 213.6 million recorded in the same period of the previous year. The loss for the period amounted to RMB 134.8 million, a 35.5% reduction from the RMB 208.8 million loss in the first half of 2024. Venus MedTech continues its focus on the research, development, manufacturing, and sale of bioprosthetic heart valves. The company was listed on the Main Board of The Stock Exchange of Hong Kong Limited on December 10, 2019.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Venus MedTech HangZhou Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}